Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder Cancer
Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.
Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.
The study evaluated atezolizumab given every three weeks at 1,200 mg. It also investigated the role of PD-L1 expression in the tumor immune cells, says Petrylak. It was determined that there was a better response rate in patients who were strong expressers of PD-L1 in the immune cells.
Previous trials have shown that there is no correlation between tumor cell expression of PD-L1 and outcome with anti PD-1 agents, explains Petrylak. However, when looking at just the immune cells, a positive relationship between PD-L1 expression and improved outcome with anti PD-1 agents was found.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
